Zacks Research Has Bearish Forecast for Sanofi Q2 Earnings

Sanofi (NASDAQ:SNY - Free Report) - Equities researchers at Zacks Research decreased their Q2 2025 EPS estimates for shares of Sanofi in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst K. Shah now anticipates that the company will post earnings of $0.93 per share for the quarter, down from their previous estimate of $0.94. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi's Q4 2025 earnings at $0.96 EPS, FY2025 earnings at $4.34 EPS, Q2 2026 earnings at $1.06 EPS and Q3 2026 earnings at $1.44 EPS.

Several other analysts have also commented on the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $60.00.

Sanofi Trading Down 1.5 %

Sanofi stock traded down $0.81 during trading on Monday, reaching $54.14. The company had a trading volume of 2,239,310 shares, compared to its average volume of 2,410,019. The firm has a market capitalization of $137.40 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock's 50 day moving average price is $51.38 and its two-hundred day moving average price is $52.58.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SNY. Brucke Financial Inc. acquired a new stake in Sanofi during the fourth quarter worth about $470,000. Forum Financial Management LP lifted its position in Sanofi by 76.1% in the fourth quarter. Forum Financial Management LP now owns 66,827 shares of the company's stock valued at $3,223,000 after acquiring an additional 28,879 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $305,000. Parr Mcknight Wealth Management Group LLC purchased a new stake in shares of Sanofi during the 4th quarter worth $1,574,000. Finally, WCG Wealth Advisors LLC grew its stake in Sanofi by 4.6% in the 4th quarter. WCG Wealth Advisors LLC now owns 36,034 shares of the company's stock valued at $1,738,000 after acquiring an additional 1,578 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.